argenx NV ADR (ARGX)vsIncyte Corporation (INCY)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
INCY
Incyte Corporation
$122.19
+0.59%
HEALTHCARE · Cap: $25.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Incyte Corporation generates 9% more annual revenue ($5.82B vs $5.32B). ARGX leads profitability with a 32.3% profit margin vs 27.7%. ARGX appears more attractively valued with a PEG of 1.27. INCY earns a higher WallStSmart Score of 76/100 (B+).
ARGX
Strong Buy73
out of 100
Grade: B
INCY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Margin of Safety
+84.0%
Fair Value
$619.23
Current Price
$122.19
$497.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 41.9%
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 25 in profit
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : INCY
The strongest argument for INCY centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 27.7% and operating margin at 41.9%. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : INCY
The primary concerns for INCY are PEG Ratio.
Key Dynamics to Monitor
INCY carries more volatility with a beta of 0.77 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INCY scores higher overall (76/100 vs 73/100), backed by strong 27.7% margins and 37.7% revenue growth. ARGX offers better value entry with a 64.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?